NPS Pharmaceuticals Reports Second Quarter 2013 Financial Results and Provides Business Update

-- U.S. launch of Gattex® (teduglutide) accelerating with net product sales of $4.8 million in quarter --

 

-- $25 to $30 million in full-year net global Gattex® sales expected with 275 to 325 patients on therapy by year end --

-- Ex-U.S. markets expected to double global peak sales opportunity for Gattex®/Revestive® --

-- Natpara fill-finish manufacturing issue successfully addressed and submission of Biologic License Application expected in fourth quarter --

-- Conference call today at 5:00 PM ET –-

 

NPS Pharmaceuticals, Inc. (NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, reported its results for the second quarter ended June 30, 2013.

Published: 09 August 2013
Written by Editor
Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  
Read more: NPS Pharmaceuticals Inc ( NPSP )

Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$21.7 Million in Equity Financing

Company to Receive Upfront US$11 Million Upon Closing

Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to US$21 million by purchasing 2,625,298 units of the Company at a price of US$4.19 per common share.

Each unit consists of (i) one common share, (ii) 0.325 Common Share purchase warrant with a purchase price of US$4.60 per whole warrant and (iii) 0.4 Common Share purchase warrant with a purchase price of US$6.50 per whole warrant.  

Published: 02 August 2013
Written by Editor
TSX   Nasdaq   Healthcare   Up on News   Financing   Interesting News  
Read more: Transition Therapeutics Inc ( TTH / TTHI )

Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals

Transaction Adds Complementary Antibacterial Drug DIFICID® for CDAD and Bolsters Cubist’s Leadership in Acute Care Hospital Market

Transaction Expected to be Accretive in First Year Post Closing

DIFICID Co-Promote Agreement Extended

Cubist Pharmaceuticals, Inc. (CBST) and Optimer Pharmaceuticals, Inc. (OPTR) today announced that they have signed a merger agreement under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or approximately $535 million on a fully diluted basis. In addition to the upfront cash payment, each stockholder of Optimer will receive a Contingent Value Right (CVR), which is expected to be publicly traded, entitling the holder to receive an additional one-time cash payment of up to $5.00 for each share they own if certain net sales of DIFICID®(fidaxomicin) are achieved, or a total transaction value of up to $801 million on a fully diluted basis. The transaction has been approved by the Boards of Directors of both companies. Cubist will host a conference call and webcast today at 6:00 p.m. ET (details below).

Published: 31 July 2013
Written by Editor
Nasdaq   Healthcare   M & A   Up on News   Interesting News  
Read more: Cubist Pharmaceuticals Inc ( CBST )

Cubist Pharmaceuticals to Acquire Trius Therapeutics

Adds Highly Complementary, Late-Stage Antibiotic Candidate, Tedizolid, and Bolsters Cubist’s Global Leadership in the Acute Care/Hospital Environment

Cubist Pharmaceuticals, Inc. (CBST) and Trius Therapeutics, Inc. (TSRX) today announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or approximately $707 million on a fully diluted basis. In addition to the upfront cash payment, each Trius stockholder will receive one Contingent Value Right (CVR), entitling the holder to receive an additional cash payment of up to $2.00 for each share they own if certain commercial sales milestones are achieved. The total transaction is valued at up to $818 million on a fully diluted basis.

Published: 31 July 2013
Written by Editor
Nasdaq   Healthcare   M & A   Up on News   Interesting News  
Read more: Trius Therapeutics Inc ( TSRX )

ImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by Jeremy Rudnick, MD, and ImmunoCellular is supporting the trial by providing the ICT-121 vaccine. ICT-121 is a dendritic cell vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.

Published: 30 July 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: ImmunoCellular Therapeutics Ltd ( IMUC )
  1. Aegerion Pharmaceuticals Inc ( AEGR )
  2. Vanda Pharmaceuticals Inc ( VNDA )
  3. Stereotaxis Inc ( STXS )
  4. Prana Biotechnology ( PRAN )
  5. Synta Pharmaceuticals Corp ( SNTA )